Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?
Mineralys Therapeutics (MLYS) recently faced removal from Russell indices but simultaneously reported positive ENDO 2026 data, announced a $150M public offering, and secured full global rights to its drug lorundrostat, along with significant loan financing. These financial and strategic moves are aimed at strengthening the company's position to advance its lead program toward its December 22, 2026 PDUFA date for FDA review, despite increased financial obligations. The article suggests these developments could significantly alter MLYS's investment narrative by providing better funding for commercialization and post-approval studies.
Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?
Mineralys Therapeutics (MLYS) was recently removed from several Russell indices, but simultaneously reported new data for lorundrostat, announced a $150 million public offering, and secured expanded global rights and significant loan financing for its lead program. These developments suggest a stronger financial position for the company to advance lorundrostat, despite the index removals. Investors now need to assess how these changes impact the company's investment narrative, especially concerning its upcoming PDUFA date on December 22, 2026, and its potential to transition from an R&D phase to a commercial hypertension franchise.
Have Insiders Sold Mineralys Therapeutics Shares Recently?
Mineralys Therapeutics President Jon Congleton recently sold US$2.0m worth of shares, decreasing his holding by 14%. This sale, along with a larger one earlier in the year, indicates a trend of insider selling. Despite existing insider ownership, the lack of recent insider buying and the relatively low insider ownership raise caution for potential investors.
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger
Mineralys Therapeutics Inc. (MLYS) has secured a significant $500 million loan from Pharmakon Advisors, following a revised agreement with Tanabe Pharma that grants MLYS full worldwide rights to lorundrostat. This financing is intended to support the company's growth and commercialization plans for its primary drug candidate, lorundrostat, which treats cardiorenal conditions. The deal comes after Goldman Sachs reiterated a Buy rating with a $42 target price for MLYS.
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?
Mineralys Therapeutics, Inc. (MLYS) is highlighted as a promising biotech stock due to new data presented on lorundrostat's potential in addressing heart failure risk. The company also recently announced a public offering of 5.66 million shares at $26.50 each to fund a portion of a $200 million royalty obligation repurchase, strengthening its financial position for future growth. MLYS is a clinical-stage company developing therapies for aldosterone-driven diseases.
Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing
An insider at Mineralys Therapeutics sold shares worth $1,960,601, as disclosed in a recent SEC filing. This transaction involved selling 99,990 shares at an average price of $19.61. The insider now directly owns 1,178,397 shares of the company.
Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing
An insider at Mineralys Therapeutics sold shares valued at $1,960,601, as per a recent SEC filing. This transaction was published on July 1, 2026. The article is reserved for members only, requiring registration to view the full content.
Mineralys (NASDAQ: MLYS) CCO sells shares after option exercise
Mineralys Therapeutics' Chief Commercial Officer, Eric Warren, exercised stock options for 104,124 shares at $13.24 per share and subsequently sold all of them at a weighted-average price of $25.8953 per share. These transactions were pre-scheduled under a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Following these sales, Warren directly holds 38,400 shares of Mineralys common stock.
Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing
An insider at Mineralys Therapeutics, Inc. (MLYS) sold shares valued at $2,696,322, as reported in a recent SEC filing. The company is a biopharmaceutical firm focused on developing treatments for hypertension and related cardiorenal conditions using its product candidate lorundrostat. Mineralys Therapeutics has also recently been involved in significant financial activities, including a $150 million stock offering and a senior secured term loan agreement.
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock
Jon Congleton, CEO of Mineralys Therapeutics (NASDAQ:MLYS), sold 75,000 shares of company stock for approximately $1.96 million on June 30, 2026. These transactions were executed under a Rule 10b5-1 trading plan, and he now directly owns 614,321 shares. The sale comes as MLYS stock has nearly doubled in the past year, trading at $26.99, and is considered overvalued by InvestingPro analysis, despite analysts setting price targets between $30 and $56.
Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting
Mineralys Therapeutics (MLYS) filed a Form 144 disclosing proposed sales of Common Stock by an affiliate, which included prior transfers of 75,000 shares for $1,970,520.69 on March 31, 2026, and 15,730 shares for $421,979.55 on April 13, 2026. The filing also detailed scheduled vesting of restricted share unit (RSU) awards on future dates: 24,619 shares on July 10, 2024, 35,954 shares on October 10, 2024, and 14,427 shares on January 10, 2025. The document serves as a procedural notice for sales of restricted or control securities and does not explain the trading motive.
Form 4 Mineralys Therapeutics Inc For: 30 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Mineralys Therapeutics Inc. dated June 30. It provides no further details beyond stating the filing's existence and the company involved.
Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan
Mineralys Therapeutics (MLYS) CEO Jon Congleton sold a total of 75,000 shares of common stock in open-market transactions on June 30, 2026. These sales, executed under a Rule 10b5-1 trading plan adopted in December 2025, involved two blocks of shares at weighted-average prices of $25.9432 and $26.8174. Congleton retains a significant direct stake in the company after these transactions.
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock By Investing.com
Mineralys Therapeutics CEO Jon Congleton sold 75,000 shares of the company's common stock for approximately $1.96 million on June 30, 2026, under a Rule 10b5-1 trading plan. Despite the insider sale, MLYS stock has seen a nearly 100% increase over the past year and analysts project price targets between $30 and $56, though InvestingPro analysis suggests it may be overvalued. The company recently announced a public offering of shares to raise $150 million and conducted financial transactions to repurchase royalty obligations.
Form 144 Mineralys Therapeutics For: 29 June By Investing.com
This article from Investing.com announces a Form 144 filing for Mineralys Therapeutics, dated June 29. It briefly mentions the stock symbol MLYS and its recent performance, with the main content being the title itself. The page also includes various market data, popular news headlines, and promotional content from Investing.com.
Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise
Mineralys Therapeutics (NASDAQ: MLYS) has filed a Form 144 notice indicating the proposed sale of 104,124 shares of Common Stock. This transaction, stemming from the exercise of employee stock options via a broker-assisted cashless exercise on June 26, 2026, is valued at $2,696,321.98. The filing also notes 82,498,101 shares outstanding as of the same date and names Merrill Lynch as the broker.
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell Microcap Index
Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) has been removed from the Russell Microcap Index, as announced on June 29, 2026. The biopharmaceutical company, which focuses on developing treatments for hypertension and related comorbidities, also saw recent announcements regarding its presentation of late-breaking data and a significant stock offering and loan agreement. This drop from the index follows a series of other recent news items for the company.
Price to earnings forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS
This article provides the "Price to earnings forward" metric for Mineralys Therapeutics, Inc. (NASDAQ: MLYS). It indicates that the market was closed with no trades at the time of publication. The data is presented within the context of TradingView's financial analytics platform.
Enterprise value to EBITDA forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS
This article provides the enterprise value to forward EBITDA for Mineralys Therapeutics, Inc. (NASDAQ: MLYS). It presents financial data for the company on the TradingView platform, noting that the market is currently closed.
MLYS Forecast — Price Target — Prediction for 2027
This article provides a forecast for Mineralys Therapeutics, Inc. (MLYS) stock, including analyst price targets and ratings. It details the company's recent stock performance, financial data like EPS and revenue, and answers frequently asked questions about its stock. The forecast indicates analyst price targets ranging from $30.00 to $56.00, with an overall "buy" signal based on the 1-month rating.
Price to sales forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS
This article briefly presents the "Price to sales forward" metric for Mineralys Therapeutics, Inc. (NASDAQ: MLYS). It indicates that the information was made by "humans" and is available in English, with market data provided by ICE Data Services and reference data by FactSet.
Mineralys Therapeutics, Inc. Actuals & Estimates (NASDAQ:MLYS)
This article provides an overview of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), including current stock price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions regarding its stock ticker, volatility, market capitalization, earnings reports, revenue, net income, and dividend policy. The article also provides details on how to buy MLYS stock and offers technical analysis ratings.
Mineralys Therapeutics CMO Rodman sells $350,086 in stock
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold $350,086 worth of company stock through pre-arranged trading plans in mid-June 2026, while also acquiring over $100,000 worth of shares through stock option exercises. The company's stock has seen an 83% gain over the past year but is considered overvalued by InvestingPro's Fair Value analysis. Recent company news includes a public offering to raise $150 million and a $750 million deal to repurchase royalty obligations for its drug lorundrostat, which is currently undergoing FDA review.
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
Mineralys Therapeutics (MLYS) has priced a $150 million public offering of common stock at $26.50 per share. The proceeds are intended to fund a significant portion of a $200 million upfront payment to repurchase royalty obligations from Tanabe Pharma Corporation, following a new $500 million debt facility. The company focuses on developing therapeutics for cardiorenal conditions, including its drug lorundrostat.
Mineralys Therapeutics director Karydas sells $75,000 in stock
Mineralys Therapeutics Director Daphne Karydas sold 3,000 shares of common stock for $75,000 after exercising options to acquire the shares. This transaction, executed under a Rule 10b5-1 trading plan, leaves Ms. Karydas with 6,200 shares and 38,000 stock options, while the stock is considered overvalued by InvestingPro.
Mineralys Therapeutics Inc (MLYS) Institutional Confidence
This article examines the institutional confidence in Mineralys Therapeutics Inc (MLYS) by detailing recent changes in institutional shareholdings. Several major investment firms, including Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A., have significantly increased their stakes, indicating growing investor interest. The company's stock is currently trading at $25.14, up 4.79%.
Mineralys Therapeutics CMO Rodman sells $350,086 in stock
David Malcom Rodman, CMO of Mineralys Therapeutics (NASDAQ:MLYS), sold company stock worth $350,086 under a pre-arranged trading plan, while also acquiring shares through stock option exercises totaling $101,946. These transactions occurred as the company reported a public offering for $150 million, a large royalty obligation repurchase deal, and continued FDA review for its drug lorundrostat, with analysts maintaining varying ratings and price targets.
Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold a total of 14,474 shares of common stock in mid-June through open-market transactions, facilitated by exercising stock options for 8,126 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025. After these sales, Rodman directly holds 57,095 shares of common stock.
Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan
Mineralys Therapeutics director Daphne Karydas executed a transaction under a Rule 10b5-1 plan, exercising stock options for 3,000 shares at $12.02 per share and simultaneously selling those 3,000 shares at $25.00 per share. After these trades, Karydas holds 6,200 shares directly. The plan was adopted on December 30, 2025, and the options had a vesting schedule of 36 monthly installments starting October 13, 2023.
Mineralys Therapeutics (NASDAQ: MLYS) files Form 144 to sell 4,584 shares
Mineralys Therapeutics (MLYS) has filed a Form 144, indicating an intended sale of 4,584 shares of common stock. This sale is a broker-assisted cashless exercise linked to employee stock options, scheduled for June 17, 2026. The filing also details previous open-market sales by David Rodman between March and June 2026.
Mineralys Therapeutics (MLYS) Rule 144: 3,000-share cashless exercise
Mineralys Therapeutics (MLYS) filed a Rule 144 notice disclosing a broker-assisted cashless exercise of 3,000 shares of common stock on June 17, 2026. The transaction generated $75,000 in proceeds for seller Daphne Karydas, stemming from the exercise of employee stock options. This filing indicates the intent to sell and the mechanism but does not detail subsequent open-market sales.
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
Mineralys Therapeutics (MLYS) has announced the pricing of a $150 million public offering of its common stock, with approximately 5.66 million shares at $26.50 each. The proceeds will primarily fund a $200 million upfront payment to repurchase royalty obligations from Tanabe Pharma Corporation, following a new $500 million debt facility. The company specializes in therapeutics for cardiorenal conditions and is developing lorundrostat.
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
Mineralys Therapeutics (MLYS) announced the pricing of a $150 million public offering of approximately 5.66 million shares of its common stock at $26.50 per share. The proceeds will primarily fund a $200 million upfront payment to repurchase royalty obligations from Tanabe Pharma Corporation, following a new $500 million committed debt facility. The company develops therapeutics for cardiorenal conditions and is working on lorundrostat, an aldosterone synthase inhibitor.
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise
Mineralys Therapeutics (MLYS) filed a Form 144, detailing proposed sales of common stock and recent dispositions by an affiliate. The filing indicates a broker-assisted cashless exercise yielding 3,542 shares on June 15, 2026, and RSU vesting of 6,348 shares on February 28, 2023. Additionally, it itemizes multiple sales by David Rodman between March 9, 2026, and June 12, 2026, with proceeds shown for each transaction, which is considered routine affiliate resale disclosure rather than a transformative corporate action.
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics presented new data at ENDO 2026 showing that lorundrostat, an investigational drug for hypertension, significantly reduced heart failure risk biomarkers in patients with uncontrolled hypertension. The analysis of data from the Launch-HTN and Advance-HTN trials suggests that lorundrostat favorably modulates physiological processes that drive heart failure by reducing markers of fibrosis and cardiac risk. The drug is currently under FDA review, with a PDUFA target date of December 22, 2026.
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics presented late-breaking data at ENDO 2026, showing that its drug lorundrostat influences heart failure risk biomarkers. A proteomic analysis of 1,004 participants revealed that lorundrostat led to significant reductions in 6 of 11 candidate causal heart failure biomarkers, including NT-proBNP, and coordinated changes in fibrosis and hemostasis markers. These findings suggest lorundrostat's potential therapeutic role in heart failure, with the drug currently under FDA review with a PDUFA target date of December 22, 2026.
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis
Mineralys Therapeutics announced that its investigational drug, lorundrostat, significantly reduced heart failure risk biomarkers in patients with uncontrolled hypertension, as revealed by proteomic analyses from the Launch-HTN and Advance-HTN trials. These findings, presented at ENDO 2026, suggest lorundrostat favorably modulates pathological processes related to heart failure, specifically engaging the renin-angiotensin-aldosterone system and reducing fibrosis markers. The drug is currently under FDA review, with a target decision date of December 22, 2026, indicating potential therapeutic benefits for a significant patient population.
Mineralys Therapeutics (MLYS) CMO sells 8,519 shares after option exercises
Mineralys Therapeutics' Chief Medical Officer, David Malcom, exercised options and sold a total of 8,519 shares of common stock on June 10 and June 12, 2026. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sales, Malcom directly holds 63,443 shares of Mineralys common stock.
Mineralys Therapeutics (NASDAQ: MLYS) files Rule 144 disclosing 6,349‑share cashless exercise
Mineralys Therapeutics (NASDAQ: MLYS) filed a Rule 144 notice disclosing a 6,349-share cashless exercise of employee stock options on June 12, 2026. The filing also detailed multiple open-market dispositions by David Rodman between March and June 2026. This notice provides transparency regarding the sale of restricted securities by insiders.
Akin Advises Pharmakon Advisors in $500 Million Senior Secured Term Loan to Mineralys Therapeutics
Akin advised Pharmakon Advisors, LP, and the BioPharma Credit funds, in connection with a senior secured term loan of up to $500 million to Mineralys Therapeutics, Inc. The first tranche of $100 million was funded at closing. Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines for hypertension and related comorbidities.
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat
Mineralys Therapeutics (MLYS) announced plans to repurchase potential royalty payments for its blood pressure drug, lorundrostat, from Tanabe Pharma Corporation for an upfront payment of $200 million and up to $100 million in commercial milestones. This move also transfers intellectual property rights to Mineralys and is being funded by a $500 million senior secured term loan from Pharmakon Advisors and a separate $150 million stock offering. Lorundrostat is an aldosterone synthase inhibitor in development for various cardiorenal conditions.
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat
Mineralys Therapeutics (MLYS) is repurchasing potential royalty payments for its blood pressure drug, lorundrostat, from Tanabe Pharma Corporation for $200 million upfront and up to $100 million in commercial milestones. To finance this, Mineralys secured a $500 million senior secured term loan with Pharmakon Advisors and launched a separate $150 million stock offering. The company is focused on developing lorundrostat for cardiorenal conditions like chronic kidney disease and hypertension.
[144] Mineralys Therapeutics, Inc. SEC Filing
Mineralys Therapeutics, Inc. has filed a Form 144 to report a proposed sale of 2,170 shares of common stock through a broker-assisted cashless exercise on June 10, 2026. The filing also details multiple past dispositions by the same reporting person, David Rodman, between March and May 2026, including a sale of 14,058 shares for over $369,000. This is a routine regulatory notice for affiliate share sales and employee stock option exercises.
5 Best AI Driven Biotech Stocks to Invest In
Mineralys Therapeutics Inc. (NASDAQ: MLYS) is highlighted as one of the top AI-driven biotech stocks. The company recently announced a significant financial transaction to repurchase potential royalty payments and intellectual property rights for its blood pressure drug, lorundrostat, from Tanabe Pharma Corporation. This move was funded through a senior secured term loan and a separate stock offering.
5 Best AI Driven Biotech Stocks to Invest In
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is highlighted as one of the best AI-driven biotech stocks. The company recently announced a major update regarding its blood pressure drug, lorundrostat, repurchasing potential royalty payments from Tanabe Pharma Corporation for up to $300 million and securing $500 million in debt financing, along with a $150 million stock offering to fund this acquisition. Mineralys specializes in developing therapeutics for conditions like chronic kidney disease and hypertension, targeting dysregulated aldosterone.
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics will present late-breaking data from a post hoc analysis of circulating proteomic data from its Launch-HTN and Advance-HTN trials at ENDO 2026. The presentation will focus on how lorundrostat modulates heart failure risk biomarkers in participants with uncontrolled hypertension. Lorundrostat is an investigational, orally administered, highly selective aldosterone synthase inhibitor aimed at treating hypertension and related comorbidities.
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, taking place in Miami from June 8-10, 2026. Management will hold a fireside chat on June 9, 2026, at 2:40 PM ET, which will also be accessible via webcast. The company focuses on developing treatments for hypertension and related conditions like chronic kidney disease and obstructive sleep apnea.
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami
Mineralys Therapeutics (NASDAQ: MLYS) announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami. Management will hold a fireside chat on June 9, 2026, at 2:40 PM ET, with a live webcast available. The company focuses on developing medicines for hypertension and related conditions like chronic kidney disease and obstructive sleep apnea.
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics, a biopharmaceutical company focusing on treatments for hypertension and related conditions, announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Management will engage in a fireside chat on June 9, 2026, which will also be available via live webcast. The company is developing lorundrostat, an aldosterone synthase inhibitor, for its lead product candidate.
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami. Management will present at a fireside chat on June 9, 2026, at 2:40 PM ET, which will also be available via live webcast. The company focuses on developing treatments for hypertension and related conditions like chronic kidney disease and obstructive sleep apnea.
